Esperion One-Ups Rival Cholesterol Drug in Midstage Study
Insights - Esperion Therapeutics Inc (ESPR) hit a home run with top-line results from ETC-1002-008, a 12-week Phase 2b study that is one of the largest ever … Continue Reading
Read nowSearch Results for gene therapy
Merrimack and Baxter Tie Up for Pancreatic Cancer Drug
Insights - Merrimack Pharmaceuticals (NASDAQ:MACK) and Baxter (NYSE:BAX) have climbed into bed on MM-398, Merrimack’s drug candidate for the treatment of metastatic pancreatic cancer, in a licensing deal worth … Continue Reading
Read now
Medivation: Strong XTANDI Performance Warrants Continued Exposure
Research - We’ve considered Medivation (MDVN) a long-term play on the clinical and commercial strength of XTANDI (enzalutamide), which with the aid of Astellas (ALPMY) is well on its way toward … Continue Reading
PremiumA Strategy for Alcobra’s Do or Die Phase 3 Results
Research - A risk-mitigating strategy for being involved in Alcobra’s (ADHD) upcoming phase 3 results in ADHD.
Premium
GlaxoSmithKline Isn’t Buying Tekmira for its Ebola Drug
Insights - Ebola stocks are still in vogue, though for new reasons on Thursday. The DailyMail reported on Wednesday evening that up to four drug companies, including Shire … Continue Reading
Read now
Buyers are Supposedly Circling InterMune: Here’s Our Take
Research - InterMune’s (ITMN) stock rose 14 percent last Wednesday, closing at a 14-year high of $52.06, on rumors that big pharma is lining up to bid for … Continue Reading
Read now
Another Big Week for RNAi Therapeutics
Insights - Arrowhead Research (ARWR) raised as many questions as it answered this week when the company reported interim results from a mid-stage study of hepatitis B drug … Continue Reading
Read now